

Immunization Directive

Number:	Imm - 4
Topic:	Administration of School Program Vaccines
Approved:	August 21, 2019
Reviewed:	
Revised:	March 25, 2022

Procedure

Administer the following inactivated vaccines:

Hepatitis B (HB)
Human Papillomavirus (HPV)
Meningococcal conjugate A, C, Y, W-135 (Men-C-ACYW)

Involvement of a Delegated Controlled Act: Yes No

Controlled Act #5: Administering a substance by injection or inhalation. This is a controlled act, which is in the scope of nursing practice. A member of the College of Nurses may perform a procedure within the controlled acts authorized to nursing if a physician, dentist, chiroprapist, nurse practitioner or midwife orders it.

Controlled Act #8: Prescribing, dispensing, selling or compounding a drug as defined in the Drug and Pharmacies Regulation Act, or supervising the part of a pharmacy where such drugs are kept.

Delegation of the Controlled Act

- This delegation applies to all Registered Practical Nurses (RPN), Registered Nurses (RN) and Public Health Nurses (PHN) employed by the Simcoe Muskoka District Health Unit (SMDHU) who have the knowledge, skills and judgment to administer the vaccine safely.

- Delegation of Controlled Acts in the provision of a public health program under the authority of a Medical Officer of Health is acknowledged by the College of Physicians and Surgeons as falling under circumstances where the Controlled Act may be delegated in the absence of a physician order and in the absence of the doctor-patient relationship.
- Identification of Risks: The risk of treatment includes the potential for a serious reaction or allergy along with the possibility that the client will experience medication side effects. These risks are minimized by reviewing contraindications and medical history and by instructing clients where possible on how to reduce the occurrence or severity of side effects.
- See SMDHU Policy LG0104 - *Delegation of Controlled Acts* for responsibilities of the delegator, program manager and staff. See SMDHU Policy GEN0105 - *Directives & Standing Orders* for approval process and quality assurance. See SMDHU Policy LG0101 – *Consent for Treatment* for information pertaining to obtaining consent.

Indications

All vaccines will be administered according to the current Publicly Funded Immunization Schedules for Ontario (PF Schedule).

From time to time administration of a vaccine outside of the Publicly Funded Immunization Schedule may be approved via consult with the MOH/AMOH.

Dosage and Administration:

As per the Specific Vaccine Information table in the appendix and the product monographs for each product.

For the purposes of the School Immunization Program, a 24 week minimum interval between doses for a 2 dose schedule of 0 & 6 is acceptable for HB & HPV (age 11-15 years vs. 6 months as per Panorama Forecaster. Those who are 16 years will need to follow an alternate schedule (3 dose schedule for 16-19 years of age for the purpose of vaccine catch up due to pandemic).

Nurses will store and handle the vaccine according to the manufacture's recommendation (between 2° and 8° C)

The recommended schedule is to be followed except for in extenuating circumstances where time does not allow (i.e. leaving the country for travel) when an accelerated or alternate approved schedule may be used as per the product monograph.

In the event of an interrupted schedule, nurses will refer to the Canadian Immunization Guide and/or the PF Schedule. Consultation will occur with an Immunization program manager and/or MOH/AMOH about continuing outside of the recommended schedule as needed.

For pre-vaccination counseling, vaccine preparation, vaccine administration and post-vaccination counseling nurses will follow the information outlined in Part 1: Key Immunization Information - *Vaccine Administration Practices* section in the Canadian Immunization Guide Evergreen edition <http://www.phac-aspc.gc.ca/publicat/cig-gci/p01-07-eng.php#vacc>.

Contraindications

1. An allergy to any component of the vaccine, or an anaphylactic or other allergic reaction to a previous dose of the vaccine. For a list of components refer to the table in the appendix for the specific product to be given.
2. Vaccination should be postponed in cases of severe and acute illness. A minor illness (with or without a fever), such as a mild upper respiratory infection is not a reason to postpone vaccination.
3. Anyone with a new or evolving neurological disorder that is under medical investigation is not to receive any vaccines in SMDHU clinics.
4. HPV vaccine should not be administered to women who are pregnant. Initiation or completion of the series should continue after the pregnancy

Quality Assurance

The program managers will ensure that:

- The directive is reviewed annually.
- Annual training opportunities are provided to all immunization nurses.
- A current list of nurses who have received directive training is maintained.
- Newly hired or returning nurses are provided a comprehensive orientation program, including a review of all relevant resources as outlined below.
- Team meetings are held once per month to provide updates, problem-solve and review issues related to the implementation of directives.
- All medication errors are reviewed as per agency policy.

References

Product Monographs for each product. Refer to Health Canada Drug Product Database for current product monographs.
<https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>

Ministry of Health, Ontario Public Health Standards: Requirements for Programs, Services, and Accountability, 2020.

Ministry of Health, Publicly Funded Immunization Schedules for Ontario (Current as of date of Directive)

SMDHU Policy [LG0101 - Consent for Treatment](#) – Revised September 2010

SMDHU Policy [LG0104 - Delegated Controlled Acts](#) – Revised August 25, 2010

SMDHU Policy [GEN0105 – Directives & Standing Orders](#) – Revised August 25, 2010

College of Nurses of Ontario (CNO), Practice Guideline, 41019, Directives Revised June 2020
https://www.cno.org/globalassets/docs/prac/41019_medicaldirectives.pdf

CNO, Practice Standard, 41007, Medication Revised January 2019

http://www.cno.org/docs/prac/41007_Medication.pdf

CNO, Practice Standard, 41071, Decisions about Procedures and Authority Revised January 2020

https://www.cno.org/globalassets/docs/prac/41071_decisions.pdf

The College of Physicians and Surgeons Policy #5-12 - Delegation of Controlled Acts March 2021

<https://www.cpso.on.ca/Physicians/Policies-Guidance/Policies/Delegation-of-Controlled-Acts>

Educational Resources

- Immunization Program Guidebook
- Canadian Immunization Guide, Evergreen Edition
- <http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php>

Authorized to

All RPNs, RNs and PHNs employed by the Simcoe Muskoka District Health Unit, who have received the directive training and who have the following qualifications are authorized to administer these vaccines:

- Registered Nurses and Registered Nurses (temporary) listed as a member with the College of Nurses of Ontario with no restrictions or limitations on their registration.
- Registered Practical Nurses and Registered Practical Nurses (temporary) listed as a member with the College of Nurses of Ontario with no restrictions or limitations on their registration. Registered Practical Nurses that were registered with the College of Nurses prior to 2005 must also have an advanced medication course certificate.
- Current CPR certification Level C (updated annually).
- Nursing students (RN or RPN) may administer this vaccine provided they have received the directive training and are under the supervision of an RN or RPN employed by the Simcoe Muskoka District Health Unit.

Authorization and Approval

The steps outlined in this directive, and training and resources available provide nurses with the necessary knowledge and skills to safely, effectively and ethically administer these vaccines in a clinic setting.

Charles Gardner
Medical Officer of Health

Date

Colin Lee
Associate Medical Officer of Health

Date

Lisa Simon
Associate Medical Officer of Health

Date

Deanna Thompson
Acting Vice-President, Immunization Department

Date

Review/Revision History

August 21, 2019 – Approved

August 28, 2020 - Approved

September 14, 2021 – Revised – added revised co-administration

March 25, 2022 – addition of 3 doses for catch up HB

Appendix - Specific Vaccine Information

Antigens	Name of the Vaccine	Components of the Vaccine	Age Indication as per Manufacturer	Publicly Funded (PF) in Ontario and to be administered to the following:	Dosage Route Site
HPV (Human Papilloma virus 9-valent (types 6, 11, 16, 18, 31, 33, 45, 52 and 58) recombinant)	Gardasil®9 (Merck)	<ul style="list-style-type: none"> HPV protein Excipients: yeast, aluminum (as amorphous aluminum hydroxyphosphate sulfate [AAHS] adjuvant), sodium chloride, L-histidine, polysorbate 80, sodium borate Product is latex free	Females: 9 years through 45 years Males: 9 years through 26 years	HPV vaccine is routinely given in Ontario to all students in grade 7 in the School Immunization Program. Students have until the end of grade 12 to complete their series. Immunocompetent students who start their series before their 15 th birthday receive 2 doses (0 & 6 months). Anyone who is immunocompromised or who begins their series after their 15 th birthday receive 3 doses (0, 2 & 6 months).	Dose: 0.5 mL Route: IM Site: Deltoid
Antigens	Name of the Vaccine	Components of the Vaccine	Age Indication as per Manufacturer	Publicly Funded (PF) in Ontario and to be administered to the following:	Dosage Route Site
Men-C-ACYW (Quadrivalent meningococcal conjugate Groups A, C, Y, and W-135 vaccine)	Menactra® (Sanofi Pasteur)	<ul style="list-style-type: none"> neisseria meningitidis group-specific polysaccharide antigens (A, C, Y, W-135) conjugated with diphtheria toxoid protein carrier Excipients: sodium chloride, sodium phosphate Product is latex free	9 months of age through 55 years of age	Men-C-ACYW (one dose) is routinely given in Ontario in grade 7 as part of the School Immunization Program. This is their adolescent booster dose of meningococcal vaccine (first dose given as Men-C-C at 1 year of age in Ontario) as recommended in the CIG. Once eligible for this vaccine, the student remains eligible for the vaccine. ***This vaccine is a required vaccine under the ISPA. Students who do not receive it will require a valid medical exemption or an affidavit under ISPA.	Dose: 0.5 mL Route: IM Site: Deltoid

Antigens	Name of the Vaccine	Components of the Vaccine	Age Indication as per Manufacturer	Publicly Funded (PF) in Ontario and to be administered to the following:	Dosage Route Site
HB (Hepatitis B vaccine) recombinant	Recombivax HB® (Merck)	<ul style="list-style-type: none"> Hepatitis B surface antigen <p>Excipients: amorphous aluminum hydroxyphosphate, sodium borate, sodium chloride</p> <p>Manufacturing Process Residuals: formaldehyde, yeast</p> <p>Contains latex</p>	Any age from birth onward	<p>HB vaccine is routinely given in Ontario to all students in grade 7 in the School Immunization Program. Students have until the end of grade 8 to complete their series. Due to COVID-19, students who are currently in grade 9 will have until August 31, 2021 to complete this series publicly funded.</p> <p>Grade 7 students who have been previously immunized with a complete series of HB vaccine are not to receive any further doses in the School Immunization Program.</p> <p>For students who have received a partial series of HB vaccine, refer to the table below “HB Quick Reference – <i>Grade 7 School and Public Clinics</i> to complete the series.</p>	<p>Dose: For youth 11 through 15 years of age - 2 dose schedule (1.0mL each at 0 & 6 months)</p> <p>Route: IM</p> <p>Site: Deltoid</p>
	Engerix®-B (GSK)	<ul style="list-style-type: none"> Hepatitis B surface antigen <p>Excipients: aluminum hydroxide, disodium phosphate dihydrate, polysorbate 20, sodium chloride, sodium dihydrogen phosphate dihydrate</p> <p>Manufacturing Process Residuals: yeast</p> <p>Product is latex free</p>	Any age from birth onward		<p>Dose: For youth 11 through 15 years of age - 2 dose schedule (1.0mL each at 0 & 6 months)</p> <p>Route: IM</p> <p>Site: Deltoid</p>

HB Quick Reference –School and Public Clinics

**Consent form returned and indicates YES for HB.*

Student HB Status	HB Recommendations	Communication & Documentation
No previous HB		
Age 11-15 years Age 16-19 years	<ul style="list-style-type: none"> • 2 doses HB - 6 months apart • 3 doses HB - 0, 1, 6 month 	<ul style="list-style-type: none"> • Document as received. • Send home <i>Notice of Immunization</i> form.
Complete		
<ul style="list-style-type: none"> ○ HB series <ul style="list-style-type: none"> ▪ 0, 1, 6 months ▪ 0, 1, 2, 12 ○ Twinrix® <ul style="list-style-type: none"> ▪ Junior- 0, 1, 6 ▪ Adult-0, 6-12 ▪ Adult 0, 1, 6 ▪ Adult 0, day 7, day 21, month 12 ○ Hexavalent series (DTaP-HB-IPV-Hib or INFANRIX hexa™) given as infant (2, 4, 6 months). 	<ul style="list-style-type: none"> • Give nothing 	<ul style="list-style-type: none"> • Update event status as previously immunized. • Document dates in Panorama. • Attach previously immunized sticker to <i>Notice of Immunization</i> form.
Immunized as an Infant		
<ul style="list-style-type: none"> ○ 1 valid dose <ul style="list-style-type: none"> ▪ 1 dose given ▪ 2 doses with incorrect intervals ○ 2 valid doses <ul style="list-style-type: none"> ▪ 2 doses with correct intervals 	<ul style="list-style-type: none"> • 2 doses of 1.0mL HB (5 months apart) • 1 dose of 1.0mL HB. 	<ul style="list-style-type: none"> • Ensure dates provided are entered into Panorama. • Document as received. • Send home <i>Notice of Immunization</i> form.
Incomplete Twinrix® series		
<ul style="list-style-type: none"> • Parent declines to complete Twinrix® series 		
<ul style="list-style-type: none"> • 1 valid dose of Adult Twinrix® <ul style="list-style-type: none"> ○ 1 dose given ○ 2 doses given less than 6 months apart • 2 valid doses of Junior Twinrix® <ul style="list-style-type: none"> ○ 2 doses given at correct intervals ○ 3 doses given with incorrect timing • 1 valid doses of Junior Twinrix® <ul style="list-style-type: none"> ○ 1 dose given ○ 2 or 3 doses given with incorrect timing. 	<ul style="list-style-type: none"> • 1 dose of 1.0mL HB <i>if parent does not want to complete Twinrix® series.</i> • To be given in Public Clinic only *2 doses of 0.5mL HB (5 months apart) <i>if parent does not want to complete Twinrix® series.</i> 	<ul style="list-style-type: none"> • Ensure dates provided are entered into Panorama. • Document as received (if applicable). • Send home <i>Notice of Immunization</i> form • Ensure dates provided are entered into Panorama. • Arrange for any required follow up.
Incomplete School Vaccine series- For School & Public Clinic Use		

<ul style="list-style-type: none"> ○ 1 valid dose <ul style="list-style-type: none"> ▪ 11-15 years of age and rec'd 1 dose ○ 1 valid dose prior to 16 years of age <ul style="list-style-type: none"> ▪ 16-19 years of age and rec'd 1 dose ○ 1 valid dose (received prior to turning 16) <ul style="list-style-type: none"> ▪ 20 years of age or older and rec'd 1 dose 	<ul style="list-style-type: none"> • 1 dose of 1.0mL HB – 6 months from dose 1. • After minimum interval of 1 month from valid dose, give 2 doses of 0.5mL HB (5 months apart). • After minimum interval of 1 month from valid dose, give 2 doses of 1.0mL HB (5 months apart). 	<ul style="list-style-type: none"> • Ensure dates provided are entered into Panorama. • Document as received. • Arrange for any required follow up.
---	--	--